ENTITY
Everest Medicines

Everest Medicines (1952 HK)

104
Analysis
Health CareChina
Everest Medicines Limited operates as a late clinical-stage biopharmaceutical company. The Company engages in licensing, clinical development, and commercialization of therapies for oncology, immunology, cardio-renal disease, and infectious disease. Everest Medicines markets its products in China and other emerging Asia Pacific markets.
more
24 Oct 2020 23:47

What HKEX Biotech "Step-Ups" Can Tell Us

This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...

Share

ECM Weekly (11 October 2020) - Excellence Comm, MR DIY, Converge ICT, Simcere, SciClone, JW Thera

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming...

Share
11 Oct 2020 09:34

A Different Angle - Simcere Pharmaceutical VS Everest Medicines (01952.HK)

Everest Medicines was listed in Hong Kong stock market on October 9, 2020 and closed at HK$72.75 (up 32.27% on the first day) . From the...

Logo
363 Views
Share
08 Oct 2020 12:36

Everest Medicines (云顶新耀) IPO: A Hot Deal Lacks Valuation Support

Everest raised HKD 3,281 million (USD 423\m) from its global offering and will list on the Hong Kong Stock Exchange tomorrow.

Logo
610 Views
Share
04 Oct 2020 12:46

ECM Weekly (4 October 2020) - JD Health, MINISO, Everest Med, Weihai Comm Bank, JD Digits

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming...

Share
x